Bio-Techne ( (TECH) ) has released its Q1 earnings. Here is a breakdown of the information Bio-Techne presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Bio-Techne Corporation is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, aiding in scientific investigations, drug discovery, and clinical testing. In its first quarter fiscal 2026 earnings report, Bio-Techne reported a slight decline in revenue but showed improvements in operating margins and earnings per share. The company completed the divestiture of its Exosome Diagnostics business to focus on non-CLIA based product lines, contributing to an adjusted operating margin increase to 29.9%. Despite a 1% decrease in revenue to $286.6 million, the company saw a rise in GAAP earnings per share from $0.21 to $0.24, and maintained an adjusted EPS of $0.42. Bio-Techne’s Protein Sciences segment experienced a slight decrease in sales, while the Diagnostics and Spatial Biology segment saw a significant improvement in operating margins. Looking ahead, Bio-Techne remains optimistic about its strategic focus and innovation capabilities, positioning itself for long-term value creation despite current market challenges.